Bone Abstracts

PTH replacement therapy in hypoparathyroidism (hypoPT) has become more accepted after proving successful in several clinical studies. Intact PTH (PTH1–84) was in 2012 withdrawn, leaving teriparatide (PTH1–34) the only therapeutic option available.All patients with postoperative HypoPT who changed medication from PTH1–84 (100 μg) to PTH1–34 (20 μg), after at least 12 months of conve...